H
Hertzel C. Gerstein
Researcher at Population Health Research Institute
Publications - 540
Citations - 76883
Hertzel C. Gerstein is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 104, co-authored 484 publications receiving 69624 citations. Previous affiliations of Hertzel C. Gerstein include Population Research Institute & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine
Gordon H. Guyatt,John A. Cairns,David N. Churchill,Deborah J. Cook,Brian Haynes,Jack Hirsh,Jan Irvine,Mark Levine,Mitchell Levine,Jim Nishikawa,David L. Sackett,Patrick Brill-Edwards,Hertzel C. Gerstein,James L. Gibson,Roman Jaeschke,Anthony Kerigan,Alan J. Neville,Akbar Panju,Allan S. Detsky,Murray Enkin,Pamela Frid,Martha S. Gerrity,Andreas Laupacis,Valerie A. Lawrence,Joël Ménard,Virginia Moyer,Cynthia D. Mulrow,Paul Links,Andrew D Oxman,Jack Sinclair,Peter Tugwell +30 more
TL;DR: An important goal of the medical residency program is to educate physicians in the practice of evidence-based medicine, and strategies include a weekly, formal academic half-day for residents devoted to learning the necessary skills.
Journal ArticleDOI
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
C. Cushman,Gregory W. Evans,Robert P. Byington,Jeffrey A. Cutler,Denise G. Simons-Morton,Jan Basile,Jeffrey L. Probstfield,Lois A. Katz,Kevin A. Peterson,William T. Friedewald,John B. Buse,J. Thomas Bigger,Hertzel C. Gerstein +12 more
TL;DR: In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm HG, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events.
Journal ArticleDOI
Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N. Ginsberg,Laura C. Lovato,Lawrence A. Leiter,Peter E. Linz,John B. Buse,Hertzel C. Gerstein,Jeffrey Probst,Richard H. Grimm,Faramarz Ismail-Beigi,J. Thomas Bigger,William C. Cush,Denise G. Simons-Morton,Robert P. Byington +12 more
TL;DR: The routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes does not support the routine use.
Journal ArticleDOI
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
Hertzel C. Gerstein,Johannes F.E. Mann,Qilong Yi,Bernard Zinman,Sean F. Dinneen,Byron J. Hoogwerf,Jean Pierre Hallé,James B. Young,Andrew Rashkow,Carol Joyce,Shah Nawaz,Salim Yusuf +11 more
TL;DR: The results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff.